Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats

Psychopharmacology
Katarzyna FijałAgnieszka Nikiforuk

Abstract

Some novel antipsychotics manifest antagonistic activity at serotonin-6 receptors; however, little is known about the role of 5-HT6 receptors in ameliorating sensory gating deficits. We evaluated the effects of the combined administration of the 5-HT6 receptor antagonist SB 271046 with clozapine and haloperidol, as well as the co-administration of SB 271046 or SB 399885 with risperidone and the 5-HT2A antagonist M100907, to overcome the deficits induced by MK-801 in the prepulse inhibition (PPI) test. MK-801 (0.1 mg/kg) produced reliable PPI deficits. Administration of SB 271046 (6 and 9 mg/kg), SB 399885 (3 and 6 mg/kg), clozapine (2.5 mg/kg), haloperidol (0.1 and 0.2 mg/kg), risperidone (0.25-1 mg/kg), and M100907 (0.5 and 1 mg/kg) did not affect the MK-801-induced deficits, but the administration of clozapine (5 mg/kg) did reverse the effects of MK-801. In MK-801-treated rats, the co-administration of inactive doses of clozapine (2.5 mg/kg) and SB 271046 (6 mg/kg) reversed the PPI impairments compared to animals that were administered inactive doses of either clozapine or SB 271046 alone. Co-administration of risperidone (1 mg/kg) or M100907 (0.5 mg/kg) with SB 271046 (6 mg/kg) or SB 399885 (3 mg/kg) also attenuated the MK-8...Continue Reading

References

Nov 28, 2014·Canadian Journal of Physiology and Pharmacology·Renny AbrahamShantaveer Irupannanavar
Feb 7, 2014·Reviews in the Neurosciences·Agnieszka Nikiforuk
May 28, 2016·Journal of Alzheimer's Disease : JAD·Alexandre V IvachtchenkoIlya Okun
Feb 9, 2017·Journal of Psychopharmacology·Agnieszka PotasiewiczPiotr Popik

Citations

Feb 1, 1990·Archives of General Psychiatry·D L Braff, M A Geyer
Jan 1, 1989·European Archives of Psychiatry and Neurological Sciences·H Y MeltzerS Matsubara
Aug 26, 1998·Pharmacology, Biochemistry, and Behavior·S HartN R Swerdlow
Mar 24, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·G B VartyM A Geyer
Jul 31, 1999·Schizophrenia Research·J A Frederick, J H Meador-Woodruff
Feb 13, 2001·Pharmacology, Biochemistry, and Behavior·T BastI M White
Oct 30, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Lee A DawsonP Li
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·B PouzetJorn Arnt
Apr 12, 2005·Pharmacology, Biochemistry, and Behavior·Vera BubeníkováColleen Dockery
Apr 23, 2005·Psychopharmacology·Paula D HatcherDeclan N C Jones
May 4, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Edward D LevinD Patrick Caldwell
Jul 12, 2005·Pharmacology & Therapeutics·Ellen S Mitchell, John F Neumaier
Jul 30, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leonora E LongDavid Alan Taylor
Jan 20, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Agnès L AuclairAdrian Newman-Tancredi
Sep 23, 2006·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Rudy SchreiberArjan Blokland
Oct 9, 2007·Pharmacology, Biochemistry, and Behavior·Ellen S Mitchell, John F Neumaier
Dec 21, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joshua S RodeferJorn Arnt
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Neil UptonDavid J Virley
Jul 16, 2008·Lupus·Lu FMMF in Induction Therapy for Active Lupus Nephritis in Mainland China Study Group
Jul 25, 2008·Pharmacology, Biochemistry, and Behavior·Shunsuke MaeharaHisashi Ohta
Jun 25, 2009·Biochemical Pharmacology·Hervé SchaffhauserMichael J Marino
Sep 22, 2010·Neuropsychiatric Disease and Treatment·Stephanie L Cincotta, Joshua S Rodefer
Nov 30, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Daniel KlamerErik Pålsson
Jan 5, 2011·Pharmacology, Biochemistry, and Behavior·F BorsiniTeresa Riccioni
Feb 19, 2011·International Review of Neurobiology·Alfredo MenesesCarlos Castillo
Apr 5, 2011·Behavioural Brain Research·Anand GururajanDaniel Thomas Malone
Jun 9, 2011·Current Medicinal Chemistry·D MarazzitiF Borsini

Related Concepts

Antipsychotic Effect
Receptor, Serotonin,5-HT2A
Thiophenes
Neurologic Manifestations
Assay OF Haloperidol
Serotonin Measurement
HTR2A wt Allele
Piperazines
Clozapine
Serotonin

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here